[Serological analysis of antibodies by anti-idiotypic monoclonal antibody 6B11 against ovarian carcinoma].
OBJECTIVE
To establish a method for detection of serologic antibody by anti-idiotypic monoclonal antibody 6B11 against ovarian carcinoma.


METHODS
Sera-antibody exminations from 172 cases, malignant and benign ovarian and uterine tumors as well as normal individuals as control were done respectively. 15 cases of ovarian epithelial carcinoma with 133 blood samples were examined serially by enzyme linked immunoabsorbent assay during the first 12 month after treatment.


RESULTS
The cutoff value was determined and calculated from sera of normal controls. The positivity of epithelial ovarian carcinoma was 67.3%, much higher than that in the benign ovarian tumor and malignant or benign uterine tumors with statistical significant difference. The serial examinations of the sera in 15 cases of ovarian epithelial carcinoma showed that the negative result turned from the positive one was corresponding with disease status.


CONCLUSIONS
The examination of sera-antibody tested by anti-idiotypic monoclonal antibody 6B11 may give a help for the diagnosis of ovarian carcinoma and may be used as one of the tumor markers for follow up.
Feng
J
J
Gynecologic Oncology Center, People's Hospital, Beijing Medical University.
Lü
J
J
Qian
H
H
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D018284:Cystadenocarcinoma, Serous / Q000276:immunology*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000276:immunology*; D014594:Uterine Neoplasms / Q000276:immunology*
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D014408:Biomarkers, Tumor